Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment

Advances in Protein Chemistry and Structural Biology

Volumn 102, Issue , 2016, Pages 225-265

  Syed Haneef, S A ^a   George Priya Doss, C ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Combination therapy; Lysosomal storage disorders; Personalized pharmacoperones; Pharmacological chaperone therapy

Indexed keywords

CHAPERONE; ENZYME; HYALURONIDASE; LIPID;

ASPARTYLGLYCOSAMINURIA; BETA MANNOSIDOSIS; BONE MARROW TRANSPLANTATION; CHEDIAK HIGASHI SYNDROME; CHOLESTEROL ESTER STORAGE DISEASE; COMBINATION DRUG THERAPY; CONFERENCE PAPER; CYSTINOSIS; DANON DISEASE; DISEASE CLASSIFICATION; ENZYME REPLACEMENT; FABRY DISEASE; FARBER DISEASE; FUCOSIDOSIS; GALACTOSIALIDOSIS; GAUCHER DISEASE; GENE THERAPY; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; GM1 GANGLIOSIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYALURONIDASE DEFICIENCY; LIPID DEGRADATION; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MAROTEAUX LAMY SYNDROME; METACHROMATIC LEUKODYSTROPHY; MORQUIO SYNDROME; MUCOLIPIDOSIS TYPE 1; MUCOLIPIDOSIS TYPE 2; MUCOLIPIDOSIS TYPE 3; MUCOLIPIDOSIS TYPE 4; MUCOPOLYSACCHARIDOSIS TYPE 7; MULTIPLE SULFATASE DEFICIENCY; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; NONHUMAN; OCULAR ALBINISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PYCNODYSOSTOSIS; SANDHOFF DISEASE; SANFILIPPO SYNDROME; SCHINDLER DISEASE; SIALIC ACID STORAGE DISEASE; TAY SACHS DISEASE; DRUG EFFECTS; GENETICS; LYSOSOMAL STORAGE DISEASES; LYSOSOME; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; TRENDS;

ENZYME REPLACEMENT THERAPY; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MOLECULAR CHAPERONES; PHARMACOGENETICS; PRECISION MEDICINE; PROTEOLYSIS;

EID: 84949683788     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apcsb.2015.10.001     Document Type: Conference Paper

References (148)

1. O. Abian, P. Alfonso, A. Velazquez-Campoy, P. Giraldo, M. Pocovi, and J. Sancho Therapeutic strategies for Gaucher disease: Miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase Molecular Pharmaceutics 8 6 2011 2390 2397
2. P. Alfonso, S. Pampín, J. Estrada, J.C. Rodríguez-Rey, P. Giraldo, J. Sancho, and et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations Blood Cells, Molecules & Diseases 35 2 2005 268 276
3. M. Arvio, O. Sauna-aho, and M. Peippo Bone marrow transplantation for aspartylglucosaminuria: Follow-up study of transplanted and non-transplanted patients The Journal of Pediatrics 138 2 2001 288 290
4. M. Balwani, L. Fuerstman, R.J. Desnick, B. Buckley, and M.M. McGovern Use of complementary and alternative medicine by patients with lysosomal storage diseases Genetics in Medicine: Official Journal of the American College of Medical Genetics 11 10 2009 722 727
5. K.S. Bateman, M.M. Cherney, D.J. Mahuran, M. Tropak, and M.N.G. James Crystal structure of β-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone Journal of Medicinal Chemistry 54 5 2011 1421 1429
6. J.M. Benito, J.M. García Fernández, and C. Ortiz Mellet Pharmacological chaperone therapy for Gaucher disease: A patent review Expert Opinion on Therapeutic Patents 21 6 2011 885 903
7. E.R. Benjamin, J.J. Flanagan, A. Schilling, H.H. Chang, L. Agarwal, E. Katz, and et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines Journal of Inherited Metabolic Disease 32 3 2009 424 440
8. E.R. Benjamin, R. Khanna, A. Schilling, J.J. Flanagan, L.J. Pellegrino, N. Brignol, and et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice Molecular Therapy: The Journal of the American Society of Gene Therapy 20 4 2012 717 726
9. D.W. Bolen, and I.V. Baskakov The osmophobic effect: Natural selection of a thermodynamic force in protein folding Journal of Molecular Biology 310 5 2001 955 963
10. E.J. Bonten, G. Yogalingam, H. Hu, E. Gomero, D. van de Vlekkert, and A. d'Azzo Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis Biochimica et Biophysica Acta 1832 10 2013 1784 1792
11. L. Borgwardt, C.I. Dali, J. Fogh, J.E. Månsson, K.J. Olsen, H.C. Beck, and et al. Enzyme replacement therapy for alpha-mannosidosis: 12 Months follow-up of a single centre, randomised, multiple dose study Journal of Inherited Metabolic Disease 36 6 2013 1015 1024
12. R.E. Boyd, G. Lee, P. Rybczynski, E.R. Benjamin, R. Khanna, B.A. Wustman, and et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases Journal of Medicinal Chemistry 56 7 2013 2705 2725
13. E. Braunlin, H. Rosenfeld, C. Kampmann, J. Johnson, M. Beck, R. Giugliani, and et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme®) therapy Journal of Inherited Metabolic Disease 36 2 2013 385 394
14. C.R. Brown, L.Q. Hong-Brown, and W.J. Welch Correcting temperature-sensitive protein folding defects The Journal of Clinical Investigation 99 6 1997 1432 1444
15. T.A. Burrow, and N.D. Leslie Review of the use of idursulfase in the treatment of mucopolysaccharidosis II Biologics: Targets & Therapy 2 2 2008 311 320
16. T.D. Butters, R.A. Dwek, and F.M. Platt Inhibition of glycosphingolipid biosynthesis: Application to lysosomal storage disorders Chemical Reviews 100 12 2000 4683 4696
17. B.J. Byrne, D.J. Falk, N. Clément, and C.S. Mah Gene therapy approaches for lysosomal storage disease: Next-generation treatment Human Gene Therapy 23 8 2012 808 815
18. I. Canals, N. Benetó, M. Cozar, L. Vilageliu, and D. Grinberg EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome Scientific Reports 5 2015 13654
19. J. Cellitti, Z. Zhang, S. Wang, B. Wu, D. Guiney, and M. Pellecchia Inhibitors of protein folding: DnaK: In probe reports from the NIH Molecular Libraries Program 2010
20. S.S. Chandar Mucopolysaccharidosis type I: Homology modeling and docking analysis of the lysosomal enzyme, human α-l-iduronidase African Journal of Pharmacy and Pharmacology 6 27 2012 2027 2038
21. K.-C. Chen, and C.Y.-C. Chen Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach Soft Matter 7 8 2011 4001 4008
22. S.H. Cheng, and A.E. Smith Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders Gene Therapy 10 16 2003 1275 1281
23. C. Ciron, N. Desmaris, M.-A. Colle, S. Raoul, B. Joussemet, L. Vérot, and et al. Gene therapy of the brain in the dog model of Hurler's syndrome Annals of Neurology 60 2 2006 204 213
24. J.T.R. Clarke, D.J. Mahuran, S. Sathe, E.H. Kolodny, B.A. Rigat, J.A. Raiman, and et al. An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants) Molecular Genetics and Metabolism 102 1 2011 6 12
25. J.T.R. Clarke, M.L. West, J. Bultas, and R. Schiffmann The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease Genetics in Medicine 9 8 2007 504 509
26. P.M. Conn, and J.A. Janovick Drug development and the cellular quality control system Trends in Pharmacological Sciences 30 5 2009 228 233
27. G.M. Cooper The cell: A molecular approach 2000 ASM Press Washington, DC
28. T.M. Cox Innovative treatments for lysosomal diseases Best Practice & Research. Clinical Endocrinology & Metabolism 29 2 2015 275 311
29. T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. van Weely, M. Hrebícek, and et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Lancet (London, England) 355 9214 2000 1481 1485
30. J. Dalmau Serra, I. Vitoria Miñana, R. CalderónFernández, I. Cortell Aznar, and S. Plaza Romero Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome Medicina Clínica 145 9 2015 392 398
31. C. De Duve The lysosome turns fifty Nature Cell Biology 7 9 2005 847 849
32. M. De la Mata, D. Cotán, M. Oropesa-Ávila, J. Garrido-Maraver, M.D. Cordero, M. Villanueva Paz, and et al. Pharmacological chaperones and coenzyme Q10 treatment improves mutant β-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease Scientific Reports 5 2015 10903
33. A.D. Dornelles, L.L. de Camargo Pinto, A.C. de Paula, C.E. Steiner, C.M. Lourenço, C.A. Kim, and et al. Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network Genetics and Molecular Biology 37 1 2014 23 29
34. R.A. Dwek, T.D. Butters, F.M. Platt, and N. Zitzmann Targeting glycosylation as a therapeutic approach Nature Reviews. Drug Discovery 1 1 2002 65 75
35. L. Ellgaard, and A. Helenius Quality control in the endoplasmic reticulum Nature Reviews. Molecular Cell Biology 4 3 2003 181 191
36. D. Elstein, C. Hollak, J.M.F.G. Aerts, S. van Weely, M. Maas, T.M. Cox, and et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease Journal of Inherited Metabolic Disease 27 6 2004 757 766
37. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, and et al. Safety and efficacy of recombinant human alpha-galactosidase A - Replacement therapy in Fabry's disease The New England Journal of Medicine 345 1 2001 9 16
38. J.-Q. Fan A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity Trends in Pharmacological Sciences 24 7 2003 355 360
39. J.-Q. Fan, and S. Ishii Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors The FEBS Journal 274 19 2007 4962 4971
40. F.C. Fervenza, R. Torra, and D.G. Warnock Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Biologics: Targets & Therapy 2 4 2008 823 843
41. J.J. Flanagan, B. Rossi, K. Tang, X. Wu, K. Mascioli, F. Donaudy, and et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase Human Mutation 30 12 2009 1683 1692
42. L.M. Franco, B. Sun, X. Yang, A. Bird, H. Zhang, A. Schneider, and et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II Molecular Therapy: The Journal of the American Society of Gene Therapy 12 5 2005 876 884
43. W.A. Gahl, J.G. Thoene, J.A. Schneider, S. O'Regan, M.I. Kaiser-Kupfer, and T. Kuwabara NIH conference. Cystinosis: Progress in a prototypic disease Annals of Internal Medicine 109 7 1988 557 569
44. C. Garrido, C. Paul, R. Seigneuric, and H.H. Kampinga The small heat shock proteins family: The long forgotten chaperones The International Journal of Biochemistry & Cell Biology 44 10 2012 1588 1592
45. D.P. Germain, and J.-Q. Fan Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies International Journal of Clinical Pharmacology and Therapeutics 47 Suppl. 1 2009 S111 S117
46. R. Giugliani, S. Waldek, D.P. Germain, K. Nicholls, D.G. Bichet, J.K. Simosky, and et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects Molecular Genetics and Metabolism 109 1 2013 86 92
47. G.A. Grabowski, K. Kacena, J.A. Cole, C.E.M. Hollak, L. Zhang, J. Yee, and et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 Genetics in Medicine: Official Journal of the American College of Medical Genetics 11 2 2009 92 100
48. O. Greiner-Tollersrud, and T. Berg Lysosomal storage disorders P. Saftig, Lysosomes 2005 Springer Science, Landes Bioscience New York 60 73
49. S.S. Grewal, E.G. Shapiro, W. Krivit, L. Charnas, L.A. Lockman, K.A. Delaney, and et al. Effective treatment of α-mannosidosis by allogeneic hematopoietic stem cell transplantation The Journal of Pediatrics 144 5 2004 569 573
50. A. Gritti Gene therapy for lysosomal storage disorders Expert Opinion on Biological Therapy 11 9 2011 1153 1167
51. C.N. Hahn, M. delPilar Martin, X.-Y. Zhou, L.W. Mann, and A. d'Azzo Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter Proceedings of the National Academy of Sciences of the United States of America 95 25 1998 14880 14885
52. J.W. Hanrahan, H.M. Sampson, and D.Y. Thomas Novel pharmacological strategies to treat cystic fibrosis Trends in Pharmacological Sciences 34 2 2013 119 125
53. H. Harada, H. Niiyama, A. Katoh, and H. Ikeda Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I JIMD Reports 16 2014 39 45
54. P. Harmatz, C.B. Whitley, L. Waber, R. Pais, R. Steiner, B. Plecko, and et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) The Journal of Pediatrics 144 5 2004 574 580
55. P. Harmatz, Z.-F. Yu, R. Giugliani, I.V.D. Schwartz, N. Guffon, E.L. Teles, and et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase Journal of Inherited Metabolic Disease 33 1 2010 51 60
56. J.A. Hawkins-Salsbury, A.S. Reddy, and M.S. Sands Combination therapies for lysosomal storage disease: Is the whole greater than the sum of its parts? Human Molecular Genetics 20 R1 2011 R54 R60
57. B. Hay Mele, V. Citro, G. Andreotti, and M.V. Cubellis Drug repositioning can accelerate discovery of pharmacological chaperones Orphanet Journal of Rare Diseases 10 2015 55
58. R.S. Hegde, and H.L. Ploegh Quality and quantity control at the endoplasmic reticulum Current Opinion in Cell Biology 22 4 2010 437 446
59. B.L. Hodges, and S.H. Cheng Cell and gene-based therapies for the lysosomal storage diseases Current Gene Therapy 6 2 2006 227 241
60. C.E.M. Hollak, and N.J. Weinreb The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease Best Practice & Research. Clinical Endocrinology & Metabolism 29 2 2015 205 218
61. P.M. Hoogerbrugge, O.F. Brouwer, P. Bordigoni, O. Ringden, P. Kapaun, J.J. Ortega, and et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation Lancet 345 8962 1995 1398 1402
62. J. Hopwood, and D. Brooks An introduction to the basic science and biology of the lysosome and storage diseases D. Applegarth, J. Dimmick, J. Hall, Organelle diseases 1997 Chapman and Hall Medical New York 7 35
63. M.A. Hossain, K. Higaki, M. Shinpo, E. Nanba, Y. Suzuki, K. Ozono, and et al. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts Brain & Development 2015 10.1016/j.braindev.2015.07.006
64. H.-J. Huang, C.-C. Lee, and C.Y.-C. Chen Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional Chinese medicine Evidence-Based Complementary and Alternative Medicine 2014 2014 12 (Article ID 830490)
65. Y.A. Ioannou Gene therapy for lysosomal storage disorders with neuropathology Journal of the American Society of Nephrology 11 8 2000 1542 1547
66. S. Ishii Pharmacological chaperone therapy for Fabry disease Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 88 1 2012 18 30
67. M. Jeyakumar, F. Norflus, C.J. Tifft, M. Cortina-Borja, T.D. Butters, R.L. Proia, and et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation Blood 97 1 2001 327 329
68. M. Jeyakumar, D.A. Smith, I.M. Williams, M.C. Borja, D.C.A. Neville, T.D. Butters, and et al. NSAIDs increase survival in the Sandhoff disease mouse: Synergy with N-butyldeoxynojirimycin Annals of Neurology 56 5 2004 642 649
69. F.K. Johnson, P.N. Mudd, A. Bragat, M. Adera, and P. Boudes Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers Clin Pharmacol Drug Dev 2 2013 120 132
70. E.D. Kakkis, J. Muenzer, G.E. Tiller, L. Waber, J. Belmont, M. Passage, and et al. Enzyme-replacement therapy in mucopolysaccharidosis I The New England Journal of Medicine 344 3 2001 182 188
71. R. Khanna, R. Soska, Y. Lun, J. Feng, M. Frascella, B. Young, and et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease Molecular Therapy: The Journal of the American Society of Gene Therapy 18 1 2010 23 33
72. T. Kirkegaard Emerging therapies and therapeutic concepts for lysosomal storage diseases Expert Opinion on Orphan Drugs 1 5 2013 385 404
73. E.M. Knight, H.N. Williams, A.C. Stevens, S.H. Kim, J.C. Kottwitz, A.D. Morant, and et al. Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ Molecular Psychiatry 20 1 2015 109 117
74. J. Kopecká, J. Krijt, K. Raková, and V. Kožich Restoring assembly and activity of cystathionine β-synthase mutants by ligands and chemical chaperones Journal of Inherited Metabolic Disease 34 1 2011 39 48
75. W. Krivit Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases Springer Seminars in Immunopathology 26 1-2 2004 119 132
76. W. Krivit, C. Peters, and E.G. Shapiro Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III Current Opinion in Neurology 12 2 1999 167 176
77. M. Laine, L. Ahtiainen, J. Rapola, J. Richter, and A. Jalanko Bone marrow transplantation in young aspartylglucosaminuria mice: Improved clearance of lysosomal storage in brain by using wild type as compared to heterozygote donors Bone Marrow Transplantation 34 11 2004 1001 1003
78. J.-P. Lee, M. Jeyakumar, R. Gonzalez, H. Takahashi, P.-J. Lee, R.C. Baek, and et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease Nature Medicine 13 4 2007 439 447
79. W.C. Lee, D. Kang, E. Causevic, A.R. Herdt, E.A. Eckman, and C.B. Eckman Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones The Journal of Neuroscience 30 16 2010 5489 5497
80. T. Leimig, L. Mann, M. Martin, P. del, E. Bonten, D. Persons, and et al. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells Blood 99 9 2002 3169 3178
81. S. Ling Structural bioinformatics analysis of acid alpha-glucosidase mutants with pharmacological chaperones M.A. Mahdavi, Bioinformatics - Trends and methodologies 2011 InTech European Union 313 324
82. H. Lodish, A. Berk, S.L. Zipursky, P. Matsudaira, D. Baltimore, and J. Darnell Molecular cell biology 4th ed. 2000 W. H. Freeman and Company New York
83. J. Lukas, A.-K. Giese, A. Markoff, U. Grittner, E. Kolodny, H. Mascher, and et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease PLoS Genetics 9 8 2013 e1003632
84. G.H.B. Maegawa, M. Tropak, J. Buttner, T. Stockley, F. Kok, J.T.R. Clarke, and et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis The Journal of Biological Chemistry 282 12 2007 9150 9161
85. B.L. Mark, D.J. Mahuran, M.M. Cherney, D. Zhao, S. Knapp, and M.N.G. James Crystal structure of human beta-hexosaminidase B: Understanding the molecular basis of Sandhoff and Tay-Sachs disease Journal of Molecular Biology 327 5 2003 1093 1109
86. J. Matsuda, O. Suzuki, A. Oshima, Y. Yamamoto, A. Noguchi, K. Takimoto, and et al. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis Proceedings of the National Academy of Sciences of the United States of America 100 26 2003 15912 15917
87. P.J. Meikle, J.J. Hopwood, A.E. Clague, and W.F. Carey Prevalence of lysosomal storage disorders JAMA 281 3 1999 249 254
88. J.P. Morello, U.E. Petäjä-Repo, D.G. Bichet, and M. Bouvier Pharmacological chaperones: A new twist on receptor folding Trends in Pharmacological Sciences 21 12 2000 466 469
89. O. Motabar, E. Sidransky, E. Goldin, and W. Zheng Fabry disease - Current treatment and new drug development Current Chemical Genomics 4 2010 50 56
90. C. Moyses Substrate reduction therapy: Clinical evaluation in type 1 Gaucher disease Philosophical Transactions of the Royal Society, B: Biological Sciences 358 1433 2003 955 960
91. J. Muenzer, M. Beck, R. Giugliani, Y. Suzuki, A. Tylki-Szymanska, V. Valayannopoulos, and et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey Genetics in Medicine 13 2 2011 102 109
92. J. Muenzer, J.E. Wraith, M. Beck, R. Giugliani, P. Harmatz, C.M. Eng, and et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genetics in Medicine 8 8 2006 465 473
93. A.C. Muntau, J. Leandro, M. Staudigl, F. Mayer, and S.W. Gersting Innovative strategies to treat protein misfolding in inborn errors of metabolism: Pharmacological chaperones and proteostasis regulators Journal of Inherited Metabolic Disease 37 4 2014 505 523
94. M. Mynarek, J. Tolar, M.H. Albert, M.L. Escolar, J.J. Boelens, M.J. Cowan, and et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: An analysis of 17 patients Bone Marrow Transplantation 47 3 2012 352 359
95. M. Ni, and A.S. Lee ER chaperones in mammalian development and human diseases FEBS Letters 581 19 2007 3641 3651
96. E.M. O'Leary, and S.A. Igdoura The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis Molecular Genetics and Metabolism 107 1-2 2012 173 185
97. G. Parenti Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics EMBO Molecular Medicine 1 5 2009 268 279
98. G. Parenti, G. Andria, and K.J. Valenzano Pharmacological chaperone therapy: Preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders Molecular Therapy: The Journal of the American Society of Gene Therapy 23 7 2015 1138 1148
99. G. Parenti, S. Fecarotta, G. la Marca, B. Rossi, S. Ascione, M.A. Donati, and et al. A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy Molecular Therapy: The Journal of the American Society of Gene Therapy 22 11 2014 2004 2012
100. G. Parenti, M. Moracci, S. Fecarotta, and G. Andria Pharmacological chaperone therapy for lysosomal storage diseases Future Medicinal Chemistry 6 9 2014 1031 1045
101. M.A. Passini, J.C. Dodge, J. Bu, W. Yang, Q. Zhao, D. Sondhi, and et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 26 5 2006 1334 1342
102. G.M. Pastores Agalsidase alfa (Replagal™) in the treatment of Anderson-Fabry disease Biologics: Targets & Therapy 1 3 2007 291 300
103. M. Peltola, A. Kyttälä, O. Heinonen, J. Rapola, T. Paunio, F. Revah, and et al. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse Gene Therapy 5 10 1998 1314 1321
104. D.H. Perlmutter Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking Pediatric Research 52 6 2002 832 836
105. E. Piotrowska, J. Jakóbkiewicz-Banecka, A. Tylki-Szymanska, A. Liberek, A. Maryniak, M. Malinowska, and et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients Current Therapeutic Research 69 2 2008 166 179
106. A. Pisani, L. Spinelli, B. Visciano, I. Capuano, M. Sabbatini, E. Riccio, and et al. Effects of switching from agalsidase beta to agalsidase alfa in 10 patients with Anderson-Fabry disease JIMD Reports 9 2012 41 48
107. F.M. Platt, and M. Jeyakumar Substrate reduction therapy Acta Paediatrica (Oslo, Norway: 1992). Supplement 97 457 2008 88 93
108. F.M. Platt, and R.H. Lachmann Treating lysosomal storage disorders: Current practice and future prospects Biochimica et Biophysica Acta 1793 4 2009 737 745
109. C. Porto, M. Cardone, F. Fontana, B. Rossi, M.R. Tuzzi, A. Tarallo, and et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts Molecular Therapy: The Journal of the American Society of Gene Therapy 17 6 2009 964 971
110. C. Porto, M.C. Ferrara, M. Meli, E. Acampora, V. Avolio, M. Rosa, and et al. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine Molecular Therapy 20 12 2012 2201 2211
111. D.P. Rastall, and A. Amalfitano Recent advances in gene therapy for lysosomal storage disorders The Application of Clinical Genetics 8 2015 157 169
112. C. Reiss, T. Lesnik, H. Parvez, S. Parvez, and R. Ehrlich Conformational toxicity and sporadic conformational diseases Toxicology 153 1-3 2000 115 121
113. B.A. Rigat, M.B. Tropak, J. Buttner, E. Crushell, D. Benedict, J.W. Callahan, and et al. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy Molecular Genetics and Metabolism 107 1-2 2012 203 212
114. O. Ringdén, M. Remberger, B.-M. Svahn, L. Barkholt, J. Mattsson, J. Aschan, and et al. Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single center Transplantation 81 5 2006 718 725
115. M. Rohrbach, and J.T.R. Clarke Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy Drugs 67 18 2007 2697 2716
116. S.M. Rombach, C.E. Hollak, G.E. Linthorst, and M.G. Dijkgraaf Cost-effectiveness of enzyme replacement therapy for Fabry disease Orphanet Journal of Rare Diseases 8 1 2013 29
117. A.M. Rovelli The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: An update Bone Marrow Transplantation 41 S2 2008 S87 S89
118. M.S. Sands, and B.L. Davidson Gene therapy for lysosomal storage diseases Molecular Therapy: The Journal of the American Society of Gene Therapy 13 5 2006 839 849
119. M.S. Sands, and M.E. Haskins CNS-directed gene therapy for lysosomal storage diseases Acta Paediatrica (Oslo, Norway: 1992). Supplement 97 457 2008 22 27
120. A.R. Sawkar, S.L. Adamski-Werner, W.-C. Cheng, C.-H. Wong, E. Beutler, K.-P. Zimmer, and et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles Chemistry & Biology 12 11 2005 1235 1244
121. A.R. Sawkar, W.-C. Cheng, E. Beutler, C.-H. Wong, W.E. Balch, and J.W. Kelly Chemical chaperones increase the cellular activity of N370S beta-glucosidase: A therapeutic strategy for Gaucher disease Proceedings of the National Academy of Sciences of the United States of America 99 24 2002 15428 15433
122. A.R. Sawkar, W. D'Haeze, and J.W. Kelly Therapeutic strategies to ameliorate lysosomal storage disorders - A focus on Gaucher disease Cellular and Molecular Life Sciences: CMLS 63 10 2006 1179 1192
123. R. Schiffmann, J.B. Kopp, H.A. Austin III, and et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial JAMA 285 21 2001 2743 2749
124. J.A. Schneider, K.F. Clark, A.A. Greene, J.S. Reisch, T.C. Markello, W.A. Gahl, and et al. Recent advances in the treatment of cystinosis Journal of Inherited Metabolic Disease 18 4 1995 387 397
125. S.H. Shin, S. Kluepfel-Stahl, A.M. Cooney, C.R. Kaneski, J.M. Quirk, R. Schiffmann, and et al. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone Pharmacogenetics and Genomics 18 9 2008 773 780
126. O. Staretz-Chacham, T.C. Lang, M.E. LaMarca, D. Krasnewich, and E. Sidransky Lysosomal storage disorders in the newborn Pediatrics 123 4 2009 1191 1207
127. Y. Suzuki Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease Brain & Development 35 6 2013 515 523
128. Y. Suzuki, S. Ogawa, and Y. Sakakibara Chaperone therapy for neuronopathic lysosomal diseases: Competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities Perspectives in Medicinal Chemistry 3 2009 7 19
129. V. Todde, M. Veenhuis, and I.J. van der Klei Autophagy: Principles and significance in health and disease Biochimica et Biophysica Acta 1792 1 2009 3 13
130. M.B. Tropak, J.E. Blanchard, S.G. Withers, E.D. Brown, and D. Mahuran High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones Chemistry & Biology 14 2 2007 153 164
131. M.B. Tropak, G.J. Kornhaber, B.A. Rigat, G.H. Maegawa, J.D. Buttner, J.E. Blanchard, and et al. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry Chembiochem: A European Journal of Chemical Biology 9 16 2008 2650 2662
132. M.B. Tropak, S.P. Reid, M. Guiral, S.G. Withers, and D. Mahuran Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients The Journal of Biological Chemistry 279 14 2004 13478 13487
133. A. Ulloa-Aguirre, J.A. Janovick, S.P. Brothers, and P.M. Conn Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease Traffic 5 11 2004 821 837
134. K.J. Valenzano, R. Khanna, A.C. Powe, R. Boyd, G. Lee, J.J. Flanagan, and et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders Assay and Drug Development Technologies 9 3 2011 213 235
135. J.M. Van den Hout, A.J. Reuser, J.B. de Klerk, W.F. Arts, J.A. Smeitink, and A.T. Van der Ploeg Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk Journal of Inherited Metabolic Disease 24 2 2001 266 274
136. H. Van den Hout, A.J. Reuser, A.G. Vulto, B. Christa, M. Loonen, A. Cromme-Dijkhuis, and et al. Recombinant human α-glucosidase from rabbit milk in Pompe patients Lancet 356 9227 2000 397 398
137. C. van Karnebeek, M. Dunbar, J. Davis, K. Bowden, K. Chaplin, R. Chaplin, and et al. Bone marrow transplant for a boy with alpha-mannosidosis illustrates a family's decision-making in rare diseases Rare Diseases and Orphan Drugs 1 2 2014 62 68
138. S. Virta, J. Rapola, A. Jalanko, and M. Laine Use of nonviral promoters in adenovirus-mediated gene therapy: Reduction of lysosomal storage in the aspartylglucosaminuria mouse The Journal of Gene Medicine 8 6 2006 699 706
139. C.H. Vite, J.C. McGowan, S.N. Niogi, M.A. Passini, K.J. Drobatz, M.E. Haskins, and et al. Effective gene therapy for an inherited CNS disease in a large animal model Annals of Neurology 57 3 2005 355 364
140. S.U. Walkley, M.A. Thrall, K. Dobrenis, M. Huang, P.A. March, D.A. Siegel, and et al. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease Proceedings of the National Academy of Sciences of the United States of America 91 8 1994 2970 2974
141. R.Y. Wang, O.A. Bodamer, M.S. Watson, W.R. Wilcox, and ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals Genetics in Medicine: Official Journal of the American College of Medical Genetics 13 5 2011 457 484
142. X. Wu, E. Katz, M.C.D. Valle, K. Mascioli, J.J. Flanagan, J.P. Castelli, and et al. A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease Human Mutation 32 8 2011 965 977
143. L. Xu, M.E. Haskins, J.R. Melniczek, C. Gao, M.A. Weil, T.M. O'Malley, and et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs Molecular Therapy: The Journal of the American Society of Gene Therapy 5 2 2002 141 153
144. S. Xu, Y. Lun, N. Brignol, R. Hamler, A. Schilling, M. Frascella, and et al. Coformulation of a novel human α-galactosidase A with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice Molecular Therapy: The Journal of the American Society of Gene Therapy 23 7 2015 1169 1181
145. G.H.-F. Yam, N. Bosshard, C. Zuber, B. Steinmann, and J. Roth Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants American Journal of Physiology. Cell Physiology 290 4 2006 C1076 C1082
146. Z. Yu, A.R. Sawkar, L.J. Whalen, C.-H. Wong, and J.W. Kelly Isofagomine- and 2,5-anhydro-2,5-imino-d-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention Journal of Medicinal Chemistry 50 1 2007 94 100
147. P. Zhang, B. Sun, T. Osada, R. Rodriguiz, X.Y. Yang, X. Luo, and et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease Human Gene Therapy 23 5 2012 460 472
148. A. Zimran, and D. Elstein Gaucher disease and the clinical experience with substrate reduction therapy Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 358 1433 2003 961 966